Global Plasma-derived Medicinal Products Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Plasma-derived Medicinal Products Market Research Report 2024
Plasma-derived medicinal products (PDMPs) are industrially manufactured from human plasma by pharmaceutical companies. Plasma is the liquid part of blood and it can be collected through specific procedures called plasmapheresis or obtained by the separation from the other components through physical means (centrifugation). PDMPs play a key, and sometimes non-replaceable, role in the treatment of many acute and chronic clinical conditions.
According to Mr Accuracy reports new survey, global Plasma-derived Medicinal Products market is projected to reach US$ 47160 million in 2029, increasing from US$ 28320 million in 2022, with the CAGR of 7.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Plasma-derived Medicinal Products market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Plasma-derived Medicinal Products market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
Shanghai RAAS
China Biologic Products
Hualan Biological Engineering Inc.
Beijing Tiantan Biological Products Corp
Pacific Shuanglin
Boya Bio-Pharmaceutical
Paisi Feike Biology Pharmacy Co., Ltd.
Xinjiang Deyuan Bioengineering
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Shenzhen Weiguang
Shanxi Kangbao
Nanyue Biopharming Corporation Ltd
Segment by Type
Immunoglobulins
Coagulation Factor Concentrates
Other
Emergency Care
Epidemic Diseasae
Immune System Disorder
Antibody Deficiency
Coagulation Disorder
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Plasma-derived Medicinal Products report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Plasma-derived Medicinal Products market is projected to reach US$ 47160 million in 2029, increasing from US$ 28320 million in 2022, with the CAGR of 7.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Plasma-derived Medicinal Products market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Plasma-derived Medicinal Products market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
Shanghai RAAS
China Biologic Products
Hualan Biological Engineering Inc.
Beijing Tiantan Biological Products Corp
Pacific Shuanglin
Boya Bio-Pharmaceutical
Paisi Feike Biology Pharmacy Co., Ltd.
Xinjiang Deyuan Bioengineering
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Shenzhen Weiguang
Shanxi Kangbao
Nanyue Biopharming Corporation Ltd
Segment by Type
Immunoglobulins
Coagulation Factor Concentrates
Other
Segment by Application
Emergency Care
Epidemic Diseasae
Immune System Disorder
Antibody Deficiency
Coagulation Disorder
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Plasma-derived Medicinal Products report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices